Cost-effectiveness analysis of gefitinib plus chemotherapy versus gefitinib alone for advanced non-small-cell lung cancer with EGFR mutations in China
Y Shu, Q Zhang, X He, L Chen - Cancer Management and …, 2021 - Taylor & Francis
Objective The aim of this study was to evaluate the cost-effectiveness of gefitinib plus
chemotherapy (GCP) versus gefitinib alone for advanced non-small-cell lung cancer …
chemotherapy (GCP) versus gefitinib alone for advanced non-small-cell lung cancer …
[PDF][PDF] Cost Effectiveness Analysis Of Gefitinib Plus Chemotherapy Versus Gefitinib Alone For Advanced Non-Small-Cell Lung Cancer With 2 EGFR Mutations In China …
C Li, J Meanac, B Shend - pdfs.semanticscholar.org
Objective: The aim of this study was to evaluate the cost-effectiveness of gefitinib 16 plus
chemotherapy (GCP) versus gefitinib alone for advanced non–small-cell lung 17 (NSCLC) …
chemotherapy (GCP) versus gefitinib alone for advanced non–small-cell lung 17 (NSCLC) …